These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 19389824)

  • 1. Asymmetric dimethylarginine and mortality in stages 3 to 4 chronic kidney disease.
    Young JM; Terrin N; Wang X; Greene T; Beck GJ; Kusek JW; Collins AJ; Sarnak MJ; Menon V
    Clin J Am Soc Nephrol; 2009 Jun; 4(6):1115-20. PubMed ID: 19389824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease.
    Kielstein JT; Böger RH; Bode-Böger SM; Frölich JC; Haller H; Ritz E; Fliser D
    J Am Soc Nephrol; 2002 Jan; 13(1):170-176. PubMed ID: 11752034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study.
    Fliser D; Kronenberg F; Kielstein JT; Morath C; Bode-Böger SM; Haller H; Ritz E
    J Am Soc Nephrol; 2005 Aug; 16(8):2456-61. PubMed ID: 15930091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma asymmetric dimethylarginine and incidence of cardiovascular disease and death in the community.
    Böger RH; Sullivan LM; Schwedhelm E; Wang TJ; Maas R; Benjamin EJ; Schulze F; Xanthakis V; Benndorf RA; Vasan RS
    Circulation; 2009 Mar; 119(12):1592-600. PubMed ID: 19289633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Asymmetric dimethylarginine independently predicts fatal and nonfatal myocardial infarction and stroke in women: 24-year follow-up of the population study of women in Gothenburg.
    Leong T; Zylberstein D; Graham I; Lissner L; Ward D; Fogarty J; Bengtsson C; Björkelund C; Thelle D;
    Arterioscler Thromb Vasc Biol; 2008 May; 28(5):961-7. PubMed ID: 18292394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Asymmetric Dimethylarginine Predicts Long-Term Outcome in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease.
    Vögeli A; Ottiger M; Meier MA; Steuer C; Bernasconi L; Huber A; Christ-Crain M; Henzen C; Hoess C; Thomann R; Zimmerli W; Mueller B; Schuetz P
    Lung; 2017 Dec; 195(6):717-727. PubMed ID: 28852826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Arginine, dimethylated arginine and homoarginine in relation to cardiovascular risk in patients with moderate chronic kidney disease.
    Hov GG; Aasarød KI; Sagen E; Åsberg A
    Clin Biochem; 2015 Jul; 48(10-11):646-51. PubMed ID: 25828044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma ADMA, urinary ADMA excretion, and late mortality in renal transplant recipients.
    Said MY; Bollenbach A; Minović I; van Londen M; Frenay AR; de Borst MH; van den Berg E; Kayacelebi AA; Tsikas D; van Goor H; Navis G; Bakker SJL
    Amino Acids; 2019 Jun; 51(6):913-927. PubMed ID: 30915571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Asymmetric and symmetric dimethylarginine and risk of secondary cardiovascular disease events and mortality in patients with stable coronary heart disease: the KAROLA follow-up study.
    Siegerink B; Maas R; Vossen CY; Schwedhelm E; Koenig W; Böger R; Rothenbacher D; Brenner H; Breitling LP
    Clin Res Cardiol; 2013 Mar; 102(3):193-202. PubMed ID: 23073705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Uremic Solutes With Cardiovascular Death in Diabetic Kidney Disease.
    Sapa H; Gutiérrez OM; Shlipak MG; Katz R; Ix JH; Sarnak MJ; Cushman M; Rhee EP; Kimmel PL; Vasan RS; Schrauben SJ; Feldman HI; Seegmiller JC; Brunengraber H; Hostetter TH; Schelling JR;
    Am J Kidney Dis; 2022 Oct; 80(4):502-512.e1. PubMed ID: 35351578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Asymmetrical (ADMA) and symmetrical dimethylarginine (SDMA) as potential risk factors for cardiovascular and renal outcome in chronic kidney disease - possible candidates for paradoxical epidemiology?
    Busch M; Fleck C; Wolf G; Stein G
    Amino Acids; 2006 May; 30(3):225-32. PubMed ID: 16680555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Asymmetric dimethylarginine and all-cause mortality: a systematic review and meta-analysis.
    Zhou S; Zhu Q; Li X; Chen C; Liu J; Ye Y; Ruan Y; Hei Z
    Sci Rep; 2017 Mar; 7():44692. PubMed ID: 28294182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach.
    Ravani P; Tripepi G; Malberti F; Testa S; Mallamaci F; Zoccali C
    J Am Soc Nephrol; 2005 Aug; 16(8):2449-55. PubMed ID: 15944335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relevance of uric acid and asymmetric dimethylarginine for modeling cardiovascular risk prediction in chronic kidney disease patients.
    Kanbay M; Afsar B; Siriopol D; Unal HU; Karaman M; Saglam M; Eyileten T; Gezer M; Verim S; Oguz Y; Vural A; Ortiz A; Johnson RJ; Covic A; Yilmaz MI
    Int Urol Nephrol; 2016 Jul; 48(7):1129-36. PubMed ID: 27007614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic renal impairment and DDAH2-1151 A/C polymorphism determine ADMA levels in type 2 diabetic subjects.
    Marra M; Marchegiani F; Ceriello A; Sirolla C; Boemi M; Franceschi C; Spazzafumo L; Testa I; Bonfigli AR; Cucchi M; Testa R
    Nephrol Dial Transplant; 2013 Apr; 28(4):964-71. PubMed ID: 23129820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of the endogenous nitric oxide inhibitor asymmetric dimethylarginine (ADMA) and brain-derived neurotrophic factor (BDNF) in depression and behavioural changes: clinical and preclinical data in chronic kidney disease.
    Kielstein H; Suntharalingam M; Perthel R; Song R; Schneider SM; Martens-Lobenhoffer J; Jäger K; Bode-Böger SM; Kielstein JT
    Nephrol Dial Transplant; 2015 Oct; 30(10):1699-705. PubMed ID: 26175142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized placebo-controlled trial assessing a treatment strategy consisting of pravastatin, vitamin E, and homocysteine lowering on plasma asymmetric dimethylarginine concentration in mild to moderate CKD.
    Nanayakkara PW; Kiefte-de Jong JC; ter Wee PM; Stehouwer CD; van Ittersum FJ; Olthof MR; Teerlink T; Twisk JW; van Guldener C; Smulders YM
    Am J Kidney Dis; 2009 Jan; 53(1):41-50. PubMed ID: 18786751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: relationship to treatment method and atherosclerotic disease.
    Kielstein JT; Böger RH; Bode-Böger SM; Schäffer J; Barbey M; Koch KM; Frölich JC
    J Am Soc Nephrol; 1999 Mar; 10(3):594-600. PubMed ID: 10073610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Asymmetric dimethylarginine is associated with macrovascular disease and total homocysteine in patients with type 2 diabetes.
    Krzyzanowska K; Mittermayer F; Krugluger W; Schnack C; Hofer M; Wolzt M; Schernthaner G
    Atherosclerosis; 2006 Nov; 189(1):236-40. PubMed ID: 16414052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Asymmetric dimethylarginine and clinical outcomes in chronic kidney disease.
    Lu TM; Chung MY; Lin CC; Hsu CP; Lin SJ
    Clin J Am Soc Nephrol; 2011 Jul; 6(7):1566-72. PubMed ID: 21642363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.